Glenmark Receives USFDA EIR for Goa Facility With VAI Status
New Delhi: Glenmark Pharmaceuticals Ltd (Glenmark), a research-led, global pharmaceutical company has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations manufacturing facility in Goa, India with a Voluntary Action Indicated (VAI) status.
The inspection was conducted at the Company’s manufacturing facility from June 22, 2026 to June 30, 2026.
Glenmark Pharmaceuticals' manufacturing facilities are spread across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries. It deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.